Regulus Hits GSK Milestone
Regulus Therapeutics, the Carlsbad, CA-based developer of drugs that block microRNA targets, said today it has reached the first milestone as part of its partnership with GlaxoSmithKline. Regulus has delivered specific microRNA blockers, known as anti-MIRs, in mice, and shown how they change the expression of genes in immune cells. Regulus didn’t disclose any financial terms related to reaching the milestone. Regulus was founded as a joint venture of Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS) and Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY).